Liora M Schultz
Overview
Explore the profile of Liora M Schultz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1321
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McNerney K, Schultz L
Transplant Cell Ther
. 2025 Feb;
PMID: 39993597
The global multi-institutional registration trial (ELIANA) of CD19.41BB.zeta chimeric antigen receptor (CAR) T cell therapy forged the path to the first FDA-approved CAR T product, tisagenlecleucel. Since its approval, extensive...
2.
3.
Steineck A, Chao K, Hall A, Jacoby E, Leahy A, Ligon J, et al.
Pediatr Blood Cancer
. 2025 Jan;
72(4):e31516.
PMID: 39844726
Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving treatment for children with relapsed/refractory B-cell hematologic malignancies, and remains an important investigational therapy for other childhood cancers. Yet, access...
4.
Marks L, Ritter V, Agrusa J, Agrusa J, Kamdar K, Rivers J, et al.
Blood Adv
. 2025 Jan;
9(6):1356-1365.
PMID: 39841960
Treatment options for patients with relapsed or refractory (R/R) anaplastic large cell lymphoma (ALCL) have increased in the era of targeted therapies such as brentuximab vedotin (BV) and anaplastic lymphoma...
5.
Monje M, Mahdi J, Majzner R, Yeom K, Schultz L, Richards R, et al.
Nature
. 2024 Nov;
636(8043):E6.
PMID: 39613972
No abstract available.
6.
Monje M, Mahdi J, Majzner R, Yeom K, Schultz L, Richards R, et al.
Nature
. 2024 Nov;
637(8046):708-715.
PMID: 39537919
H3K27M-mutant diffuse midline gliomas (DMGs) express high levels of the disialoganglioside GD2 (ref. ). Chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) eradicated DMGs in preclinical models. Arm A of...
7.
Monje M, Mahdi J, Majzner R, Yeom K, Schultz L, Richards R, et al.
medRxiv
. 2024 Jul;
PMID: 38978673
H3K27M-mutant diffuse midline gliomas (DMGs) express high levels of the GD2 disialoganglioside and chimeric antigen receptor modified T-cells targeting GD2 (GD2-CART) eradicate DMGs in preclinical models. Arm A of the...
8.
Bender J, Damodharan S, Capitini C, Moskop A, Toner K, Vatsayan A, et al.
Blood Adv
. 2024 Jun;
8(15):4164-4168.
PMID: 38916857
No abstract available.
9.
Lamble A, Schultz L, Nguyen K, Hsieh E, McNerney K, Rouce R, et al.
Blood Adv
. 2024 May;
8(13):3544-3548.
PMID: 38701425
No abstract available.
10.
Schultz L, Jeyakumar N, Kramer A, Sahaf B, Srinagesh H, Shiraz P, et al.
Leukemia
. 2024 Mar;
38(5):963-968.
PMID: 38491306
Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22 malignancies with progression after CD19-directed therapies. Using on-site, automated, closed-loop manufacturing, we conducted...